pirfenidone inhalation (S-770108 inhalation) / Shionogi - LARVOL DELTA

Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device (clinicaltrials.gov) - P1; N=12; Completed; Sponsor: Shionogi; Recruiting ➔ Completed; Trial completion date: Jun 2021 ➔ Dec 2020; Trial primary completion date: Jun 2021 ➔ Dec 2020

Clinical • Trial completion • Trial completion date • Trial primary completion date

Study in Healthy Adults to Quantify Lung Deposition and Distribution of Radio-labelled S-770108 Inhalation Powder Formulation Delivered by a Novel Inhaler Device (clinicaltrials.gov) - P1; N=12; Recruiting; Sponsor: Shionogi

Clinical • New P1 trial

Good news about the effectiveness of antifibrotics for IPF (Mayo Clinic) - "...Andrew Limper, M.D....evaluated the effectiveness of pirfenidone and nintedanib for patients with idiopathic pulmonary fibrosis. The researchers reported 'the medications had an association with a reduced risk of all-cause mortality and hospitalizations for up to two years.'"

Blog